Patents Assigned to Pharmascience Inc.
-
Patent number: 8765681Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R1, R2, R3, R100, R200, R300, A, A1, BG, Q and Q1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.Type: GrantFiled: November 8, 2012Date of Patent: July 1, 2014Assignee: Pharmascience Inc.Inventors: Alain Boudreault, James Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent
-
Publication number: 20140045833Abstract: The present invention relates to a novel family of inhibitors of protein kinases of Formula (1) wherein X is selected from CH2, O, S(0)n, or NR6; and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src, Btk and Lck protein kinase families.Type: ApplicationFiled: April 3, 2012Publication date: February 13, 2014Applicant: PHARMASCIENCE INC.Inventors: Alain Laurent, Yannick Rose, Stephen Morris, James Jaquith
-
Patent number: 8648094Abstract: Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.Type: GrantFiled: March 21, 2012Date of Patent: February 11, 2014Assignee: Pharmascience, Inc.Inventors: Alain Laurent, Scott Jarvis, Patrick Bureau, Alain Boudreault, James Jaquith
-
Patent number: 8575113Abstract: The present invention is directed towards an isomer, an enantiomer, a diastereoisomer, or a tautomer of a pyrrolidine compound represented by Formula I: in which the substituents R1, R1a, R2, R2a, R3, A and Q are defined herein; or a prodrug, or a salt thereof, and which bind to IAP BIR domains. In particular, the compounds are useful in treating proliferative disorders such as cancer.Type: GrantFiled: June 28, 2010Date of Patent: November 5, 2013Assignee: Pharmascience Inc.Inventors: Scott Jarvis, Alain Boudreault, Patrick Bureau, James B. Jaquith, Alain Laurent, Delphine Labit
-
Publication number: 20130071411Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R1, R2, R3, R100, R200, R300, A, A1, BG, Q and Q1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.Type: ApplicationFiled: November 8, 2012Publication date: March 21, 2013Applicant: PHARMASCIENCE INC.Inventor: Pharmascience Inc.
-
Publication number: 20130040892Abstract: A compound of Formula 1: (I) or salt thereof, as well as methods of making compounds of Formula 1, methods of using compounds of Formula 1 to treat proliferative disorders such as cancer, and related compounds, composition, and methods.Type: ApplicationFiled: February 11, 2011Publication date: February 14, 2013Applicant: PHARMASCIENCE INC.Inventors: Alain Laurent, Melanie Proulx, Yannick Rose, Irina Denissova, Kenza Dairi, Scott Jarvis, James B. Jaquith
-
Publication number: 20120195915Abstract: Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.Type: ApplicationFiled: March 21, 2012Publication date: August 2, 2012Applicant: PHARMASCIENCE INC.Inventors: Alain Laurent, Scott Jarvis, Patrick Bureau, Alain Boudreault, James Jaquith
-
Patent number: 8163792Abstract: Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.Type: GrantFiled: May 16, 2007Date of Patent: April 24, 2012Assignee: Pharmascience Inc.Inventors: Alain Laurent, Scott Jarvis, Patrick Bureau, Alain Boudreault, James Jaquith
-
Publication number: 20120046325Abstract: Methods of use and pharmaceutical compositions for a genus of low molecular weight compounds comprising optionally substituted isoxazoline ring systems that act as inhibitors of MIF (macrophage migration inhibitory factor) are disclosed. Specifically, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatoid arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular disease, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis).Type: ApplicationFiled: April 14, 2011Publication date: February 23, 2012Applicant: CYTOKINE PHARMASCIENCES, INC.Inventor: Yousef AL-ABED
-
Publication number: 20120009141Abstract: A compound of Formula 1: or a salt thereof, and methods for the use thereof, especially as an IAP inhibitor, as well as related compounds, compositions, and methods.Type: ApplicationFiled: August 7, 2009Publication date: January 12, 2012Applicant: PHARMASCIENCE INC.Inventors: Alain Laurent, Melanie Proulx, James B. Jaquith, Irina Denissova
-
Patent number: 8063095Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1 are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.Type: GrantFiled: December 4, 2006Date of Patent: November 22, 2011Assignee: Pharmascience Inc.Inventors: Alain Laurent, Kim Hewitt, Stephen Morris, Patrick Bureau, Alain Boudreault, Scott Jarvis, James Jaquith
-
Patent number: 8034840Abstract: The invention relates to pharmaceutically acceptable salts of guanylhydrazone-containing compounds, for example, Semapimod. The invention also relates to pharmaceutically acceptable compositions comprising the salts and methods for their use.Type: GrantFiled: June 22, 2007Date of Patent: October 11, 2011Assignee: Cytokine PharmaSciences, Inc.Inventor: Thais M. Seilecki-Dzurdz
-
Publication number: 20110245156Abstract: Compounds are disclosed. Compositions that include the compounds are disclosed. Methods of making and using the compounds are also disclosed.Type: ApplicationFiled: December 9, 2009Publication date: October 6, 2011Applicant: CYTOKINE PHARMASCIENCES, INC.Inventor: Thais M. Sielecki-Dzurdz
-
Publication number: 20110237679Abstract: Compounds, salts thereof, and tautomers thereof are disclosed. Compositions that include the compounds are disclosed. Methods of making and using the compounds are also disclosed.Type: ApplicationFiled: December 9, 2009Publication date: September 29, 2011Applicant: CYTOKINE PHARMASCIENCES, INC.Inventor: Thais M. Sielecki-Dzurdz
-
Publication number: 20110224301Abstract: Methods are described, which include the administration of semapimod or guanylhydrazone containing compounds, salt thereof, or a combination of the compound and a salt thereof for the inhibition, treatment, and/or prevention of any of NEC, a condition associated with the release of HMGB1, a condition associated with the release of iNOS protein, a condition associated with the release of Bax protein, a condition associated with the release of Bad protein, a condition associated with the release of COX-2 protein, or a condition associated with the release of RAGE, or a combination thereof to a subject in need thereof.Type: ApplicationFiled: September 10, 2010Publication date: September 15, 2011Applicant: CYTOKINE PHARMASCIENCES, INC.Inventors: Ruben ZAMORA, Henri R. FORD, Thais SIELECKI-DZURDZ, Vidal F. DE LA CRUZ
-
Patent number: 8012944Abstract: The invention features methods, compositions, and kits for treating a patient having a proliferative disease.Type: GrantFiled: October 28, 2004Date of Patent: September 6, 2011Assignee: Pharmascience Inc.Inventors: Eric LaCasse, Daniel McManus, Jon P. Durkin
-
Publication number: 20110144189Abstract: The present invention relates to compounds having the formula: salts thereof; compositions comprising one or more of the compounds and/or salts thereof; methods of using; and methods of making.Type: ApplicationFiled: December 7, 2010Publication date: June 16, 2011Applicant: CYTOKINE PHARMASCIENCES, INC.Inventor: Thais SIELECKI-DZURDZ
-
Patent number: 7928130Abstract: Methods of use and pharmaceutical compositions for a genus of low molecular weight compounds comprising optionally substituted isoxazoline ring systems that act as inhibitors of MIF (macrophage migration inhibitory factor) are disclosed. Specifically, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatoid arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular disease, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis).Type: GrantFiled: January 27, 2009Date of Patent: April 19, 2011Assignee: Cytokine PharmaSciences, Inc.Inventor: Yousef Al-Abed
-
Publication number: 20110020321Abstract: Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer.Type: ApplicationFiled: May 17, 2010Publication date: January 27, 2011Applicant: CYTOKINE PHARMASCIENCES, INC.Inventors: Richard J. BUCALA, Lin LENG, Christine N. METZ
-
Publication number: 20110009836Abstract: The present application discloses a pharmaceutical delivery system for delivering a desired amount of liquid in the form of droplets. The pharmaceutical delivery system comprises a container having resilient compressible walls of uniform thickness, an elongated neck, and a valveless dropper tip. The pharmaceutical delivery system dispenses liquid through an outlet orifice in the valveless dropper tip in a drop by drop manner, producing droplets of substantially uniform volume independent of the amount of pressure applied on the container.Type: ApplicationFiled: December 18, 2008Publication date: January 13, 2011Applicant: PHARMASCIENCE INC.Inventors: Chafic Chebli, Hanna Piskorz